This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Major histocompatibility complex class II deficiency주조직적합성복합체 II형 결핍

ICD-10: D81.7 | Synonyms: MHC class II deficiency, Bare lymphocyte syndrome type II (BLS II), HLA class II deficiency

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

First description

MHC class II deficiency first became known when Griscelli et al. in 1979 reported immunodeficient children whose cell surfaces did not express HLA-DR, -DQ, and -DP molecules. It was initially named 'Bare lymphocyte syndrome', and as the distinction from HLA class I deficiency (BLS type I) later became clear, it was reclassified as BLS type II.

Identification of transcriptional regulators

In the 1990s, advances in cloning technology led to the successive identification of the transcriptional regulators required for MHC class II gene expression. It was confirmed that transcription factors such as CIITA (MHC Class II Transactivator), identified by Reith et al. in 1993, and RFXANK, RFX5, and RFXAP, identified by Steimle et al. in 1994, are essential for MHC II expression.

Establishment of the classification system

By molecular cause, MHC II deficiency is classified into four complementation groups: A (CIITA variants), B (RFXANK variants), C (RFX5 variants), and D (RFXAP variants). The most common cause is RFXANK (or RFX-B) variants, which cluster in North Africa because of a founder effect.

Situation in Korea

In Korea, MHC II deficiency is a very rare disease, and a small number of cases are diagnosed and managed at institutions specializing in primary immunodeficiency.

2. Causes

Mechanism regulating MHC class II expression

Expression of the MHC class II genes (HLA-DR, HLA-DQ, HLA-DP) is regulated by the RFX transcription complex (RFX5, RFXANK, RFXAP) and CIITA. The RFX complex binds to the X box of MHC II gene promoters, and CIITA, as a coactivator, is essential for transcriptional activation by the RFX complex.

Causative genes by complementation group

Complementation groupGeneLocationFeatures
ACIITA16p13.13MHC II transcriptional coactivator; clinical course relatively mild in some cases
BRFXANK19p12Most common; North African founder effect
CRFX51q21.3Component of the RFX complex
DRFXAP13q14.11Component of the RFX complex

Founder effect

RFXANK variants (especially the Gln67X premature termination variant) cluster in North Africa and the Middle East because of a founder effect, and homozygous RFXANK variants are identified in a substantial proportion of patients from these regions.

3. Genetics

Mode of inheritance

Inheritance is autosomal recessive. All four causative genes (CIITA, RFXANK, RFX5, RFXAP) are located on autosomes. The parents are carriers, and 25% of their children are affected.

Complementation group classification and genotype-phenotype

All four complementation groups show the same phenotype (loss of HLA II expression, reduced CD4+ T cells). Clinical severity does not differ greatly by complementation group, but a relatively mild clinical course has been reported in some cases with CIITA variants (complementation group A).

Molecular diversity

Various point mutations, deletions, and splicing variants have been reported in each gene. In particular, the RFXANK Gln67X variant is repeatedly identified in North African patients.

Carrier detection

Carriers can be identified among parents and siblings by molecular genetic testing. Carriers show normal HLA II expression and have no clinical symptoms.

4. General epidemiology

Worldwide prevalence

MHC II deficiency is a rare primary immunodeficiency, with about 200 cases reported worldwide. The populations most frequently reported are those of North African (Morocco, Algeria, Tunisia) and Middle Eastern (Saudi Arabia, Iran) origin.

Age of onset and sex

Symptoms mainly appear between a few months of age and 2 years. There is no sex difference. Later onset has been reported in some cases.

Status in Korea

In Korea, MHC II deficiency is very rare, and a small number of patients managed at primary immunodeficiency centers (such as university hospitals in Seoul and Busan) have been reported. Given the ethnic background in Korea, the North African founder variant is presumed to be rare, with diverse variants occurring sporadically.

5. Pathophysiology

Failure of thymic selection of CD4+ T cells

MHC II molecules on the surface of thymic cortical epithelial cells are essential for positive selection of CD4+ T cells in the thymus. When MHC II expression is lost, positive selection of CD4+ T cells does not occur, and CD4+ T cells are markedly reduced or absent in peripheral blood.

Immune impairment due to CD4+ T-cell deficiency

CD4+ T cells (helper T cells) help B cells produce antibodies, promote CD8+ T-cell activation, and are involved in macrophage activation. When CD4+ T cells are deficient, all of these effector immune functions decline, resulting in a state of combined immunodeficiency.

Reduced antibody production

B-cell numbers are normal, but without T-cell help, class switching and production of high-affinity antibodies are impossible. As a result, serum immunoglobulins (IgG, IgA, IgM) are all reduced, or a pattern of normal IgM with reduced IgG and IgA appears.

Cell-mediated immunodeficiency

CD8+ T cells and NK cells can function independently without CD4+ T-cell help, but integrated cell-mediated immunity is reduced, making patients highly vulnerable to intracellular pathogens (mycobacteria, opportunistic viruses, fungi).

6. Symptoms

Onset in early life

Most patients first develop symptoms between 6 months and 2 years of age with recurrent severe infections. This coincides with the time when maternally transferred antibodies disappear.

Pattern of recurrent infections

Bacterial infections (pneumonia, otitis media, meningitis; pneumococcus, Haemophilus, meningococcus), viral infections (pneumonia due to CMV, EBV, adenovirus, parainfluenza virus), fungal infections (Pneumocystis jirovecii pneumonia, Candida, Aspergillus), and opportunistic infections (chronic diarrhea due to Cryptosporidium) are frequent.

Gastrointestinal symptoms

Chronic diarrhea, malabsorption, and failure to thrive due to Cryptosporidium and other opportunistic pathogens are common. Sclerosing cholangitis can develop as a complication of Cryptosporidium infection.

Live vaccine complications

Disseminated BCG infection develops after BCG vaccination, and in Korea as well, disseminated BCG infection after BCG vaccination sometimes appears as the first manifestation of the immunodeficiency.

7. Signs

Physical examination findings

Physical examination shows failure to thrive, weight loss, oral candidiasis, and stomatitis. Absent or atrophic lymph nodes without lymphadenopathy are characteristic. Abnormal auscultation findings (crackles, wheezes) due to recurrent pneumonia and chronic cough are seen.

Laboratory findings

Lymphocyte subset analysis is characterized by marked reduction or absence of CD4+ T cells. CD8+ T cells are normal or increased. B-cell numbers are normal, but serum IgG and IgA are reduced. Flow cytometry shows loss or marked reduction of HLA-DR (MHC II) expression. In lymphocyte proliferation testing, the proliferative response to alloantigens (MLR, mixed lymphocyte reaction) is reduced.

Imaging findings

Chest CT shows interstitial lung disease, pneumonia, bronchiectasis, and atelectasis. Sclerosing cholangitis may be confirmed on abdominal CT or MRCP.

8. Screening

Newborn screening

MHC II deficiency may be detected by TREC-based newborn screening, but because the pattern of CD4+ T-cell reduction is not specific, complementary confirmatory testing is needed.

Criteria for clinical suspicion

Primary immunodeficiency is suspected in infants older than 6 months with recurrent opportunistic infections, chronic diarrhea, and failure to thrive. Parental consanguinity and a similar history in family members are checked.

Basic immunological screening

After a complete blood count, lymphocyte subset analysis (confirming a marked reduction in CD4+ T cells), flow cytometry for HLA-DR expression, and quantification of serum immunoglobulins (whether IgG, IgA, IgM are reduced) are performed.

Status in Korea

In Korea, the diagnosis is made by immunological testing in infants referred for disseminated infection after BCG vaccination or symptoms of recurrent opportunistic infection. Introduction of a TREC-based screening program is expected to make early detection possible.

9. Diagnosis

Flow cytometry

The key diagnostic finding is loss or marked reduction of HLA-DR, -DQ, and -DP expression on the surface of peripheral blood lymphocytes on flow cytometry using HLA-DR (or pan-MHC II) antibodies. It is confirmed together with a reduction in CD4+ T cells.

Complementation group classification testing

The complementation group can be determined by a complementation assay, in which patient cells are fused with cell lines of each complementation group to see whether MHC II expression is restored, but in practice the causative gene is identified directly by molecular genetic testing.

Molecular genetic testing

Pathogenic variants are identified by Sanger sequencing or NGS panel testing of the CIITA, RFXANK, RFX5, and RFXAP genes. In patients of North African or Middle Eastern ancestry, the RFXANK Gln67X variant can be checked first.

Immunological function tests

Reduced proliferative response in the mixed lymphocyte reaction (MLR). Reduced antigen-specific lymphocyte proliferative responses. Functional antibody production capacity is assessed by serum immunoglobulin quantification and antibody titer testing.

10. Treatment

Hematopoietic stem cell transplantation (HSCT)

The only curative treatment for MHC II deficiency is allogeneic hematopoietic stem cell transplantation. Transplantation from an HLA-matched sibling or unrelated donor is the standard treatment. Performing transplantation as early as possible after diagnosis, before infectious complications develop, is critically important for success rates and prognosis.

Supportive care before transplantation

Antibody deficiency is compensated with intravenous immunoglobulin (IVIG). TMP-SMX for prevention of Pneumocystis pneumonia, fluconazole for Candida prophylaxis, and ganciclovir/valganciclovir for CMV prophylaxis are administered.

Management of BCG infection

When disseminated infection develops after BCG vaccination, antituberculosis treatment (isoniazid + rifampin ± ethambutol) is maintained long term while transplantation proceeds.

Contraindication of live vaccines and caution with blood products

Live vaccines such as BCG, MMR, varicella, and rotavirus are absolutely contraindicated. For transfusions, irradiated, CMV-negative, leukocyte-depleted blood products are used.

11. Prognosis

Prognosis without treatment

Without treatment, most patients with MHC II deficiency die of infection within the first few years of life. In particular, sclerosing cholangitis due to Cryptosporidium progresses even after transplantation and worsens the prognosis.

Prognosis after HSCT

Long-term survival is possible with early transplantation. Transplant success and long-term survival rates are high with HLA-matched sibling donor transplantation. However, when complications (sclerosing cholangitis, chronic lung disease) have already progressed before transplantation, morbidity remains high after transplantation.

Complication-related prognosis

In patients who developed sclerosing cholangitis due to Cryptosporidium, liver disease may persist after transplantation. Chronic lung disease, nutritional impairment, and failure to thrive are the main causes of morbidity in long-term survivors.

12. Prevention

Genetic counseling

Carrier testing of both parents and genetic counseling on the risk in subsequent pregnancies are essential.

Prenatal diagnosis and PGT-M

In pregnant women with a family history, whether the fetus is affected is determined after confirming the fetal genotype by CVS or amniocentesis. In in vitro fertilization, PGT-M can prevent implantation of affected embryos.

Contraindication of neonatal BCG vaccination

When MHC II deficiency is strongly suspected or confirmed, BCG vaccination is never given. In newborns suspected because of a family history, immune evaluation is performed before BCG vaccination.

Building an early diagnosis system

Expanded introduction of TREC-based newborn screening programs is key to early diagnosis and improved treatment outcomes.

13. References

  1. Griscelli C, Lisowska-Grospierre B, Mach B. Combined immunodeficiency with defective expression in MHC class II genes. Immunodefic Rev. 1989;1(2):135-153.
  2. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell. 1993;75(1):135-146.
  3. Reith W, Steimle V, Mach B. A major histocompatibility complex class II deficiency due to a mutation in the RFXANK gene. Nat Genet. 1995;10(4):425-432.
  4. Masternak K, Barras E, Zufferey M, et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet. 1998;20(3):273-277.
  5. Villard J, Masternak K, Lisowska-Grospierre B, et al. MHC class II deficiency: a disease of gene regulation. Medicine (Baltimore). 2001;80(6):405-418.
  6. Ouederni M, Vincent QB, Frange P, et al. Clinical features of MHC class II deficiency in 55 patients from the Maghreb. Medicine (Baltimore). 2011;90(4):237-248.
  7. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol. 1996;14:301-331.
  8. Klein C, Cavazzana-Calvo M, Le Deist F, et al. Bone marrow transplantation in major histocompatibility complex class II deficiency: a single-center study of 19 patients. Blood. 1995;85(2):580-587.
  9. Casanova JL, Jouanguy E, Lamhamedi S, et al. Immunological conditions of children with BCG disseminated infection. Lancet. 1995;346(8974):581.
  10. Picard C, Al-Herz W, Bousfiha A, et al. Primary immunodeficiency diseases: an update on the classification from the IUIS Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015;35(8):696-726.
  11. Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 2003;361(9357):553-560.
  12. Hanna S, Etzioni A. MHC class I and II deficiencies. J Allergy Clin Immunol. 2014;134(2):269-275.